gvtcx

NHS National Generic Pharmaceuticals Transition 2021_2 - Pemetrexed Solution for Infusion - LSNE

The value below is a framework or dynamic market ceiling: the maximum that could be spent across all call-offs, not the value of a single contract. Aggregate figures on this site exclude these to avoid double counting.

key details

Value£3,040
Statuscomplete
Category (CPV) 33600000
Deadline26 May 2021
Procedureopen
OCIDocds-h6vhtk-02a9fe

Award

SupplierValueDateStatus
Mylan · · active

description

NHS National Pharmaceuticals Transition 2021_2 - Pemetrexed solution for infusion LSNE region.Offer reference number: CM/PHG/21/5639/00Period of framework agreement: The total maximum duration of the framework agreement to be no more than 38 months (19 months plus options to extend (at the Authority's sole discretion) for up to a further 19 months)FIND A TENDER (FTS) Reference number: 2021/S 000-008845Potential periods of call-offs under the framework agreement: 24/06/2021 to 31/01/2023 (19 months) LSNE region.

notice history

2 notices published against this procurement.

PublishedTypeRegimeNotice
26 Apr 2021 Contract notice (F02) Earlier regulations 008845-2021
14 Jul 2021 Contract award notice (F03) Earlier regulations 016442-2021

more from The NHS Commissioning Board (operating under the name of NHS England)

all contracts from this buyer →

similar contracts awarded

Other awarded contracts in the same category. Useful for seeing who normally wins this kind of work, and at what value.

source

Published on Find a Tender. Contact details for named individuals are not reproduced on this site.